Terms: = Breast cancer AND CBL, RNF55, 867, ENSG00000110395, C-CBL, CBL2 AND Clinical Outcome
3 results:
1. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract] [Full Text] [Related]
2. Therapeutic targeting of HER2-CB
Blasco-Benito S; Moreno E; Seijo-Vila M; Tundidor I; Andradas C; Caffarel MM; Caro-Villalobos M; Urigüen L; Diez-Alarcia R; Moreno-Bueno G; Hernández L; Manso L; Homar-Ruano P; McCormick PJ; Bibic L; Bernadó-Morales C; Arribas J; Canals M; Casadó V; Canela EI; Guzmán M; Pérez-Gómez E; Sánchez C
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3863-3872. PubMed ID: 30733293
[TBL] [Abstract] [Full Text] [Related]
3. Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis.
Lee ST; Feng M; Wei Y; Li Z; Qiao Y; Guan P; Jiang X; Wong CH; Huynh K; Wang J; Li J; Karuturi KM; Tan EY; Hoon DS; Kang Y; Yu Q
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11121-6. PubMed ID: 23784775
[TBL] [Abstract] [Full Text] [Related]
